Cell-free DNA (cfDNA) analysis is transforming precision medicine, offering a non-invasive window into the body, particularly in the context of cancer. This journal collection, hosted by npj Precision ...
SAGA Diagnostics has commercially launched its Pathlight test in the US to detect residual disease and recurrence. Comprising a multi-cancer molecular residual disease (MRD) platform, the test has ...
New investigational data from Phase 1/2 study of enzomenib (DSP-5336) in patients with relapsed/refractory acute myeloid leukemia (AML) show clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback